Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28586691 | 1.00 | AAK1 (0.46) | AAK1TP53SMN1; SMN2TRPA1PRCP | |
| SCHEMBL5111381 | 0.87 | AAK1 (0.47) | AAK1PRCPL3MBTL1TSHRLMNA | |
| SCHEMBL2332614 | 0.85 | AAK1 (0.51) | AAK1TP53SMN1; SMN2TRPA1LMNA | |
| SCHEMBL1481829 | 0.85 | AAK1 (0.51) | AAK1TP53SMN1; SMN2TRPA1LMNA | |
| SCHEMBL12432831 | 0.85 | L3MBTL1 (0.46) | AAK1PRCPL3MBTL1TSHRLMNA | |
| SCHEMBL12798924 | 0.85 | AAK1 (0.48) | AAK1PRCPL3MBTL1TSHR | |
| SCHEMBL1391519 | 0.84 | L3MBTL1 (0.47) | AAK1SMN1; SMN2L3MBTL1TSHRLMNA | |
| SCHEMBL7921079 | 0.84 | AAK1 (0.47) | AAK1PRCPL3MBTL1TSHR | |
| SCHEMBL1479007 | 0.84 | AAK1 (0.49) | AAK1TP53SMN1; SMN2TRPA1LMNA | |
| SCHEMBL2332863 | 0.84 | AAK1 (0.49) | AAK1TP53SMN1; SMN2TRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| CN-113166117-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-3891142-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-113166117-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020114949-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | AAK1 2597/4885TP53 416/4885SMN1; SMN2 3647/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | AAK1 3810/4885TP53 4776/4885SMN1; SMN2 1424/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | AAK1 4457/4885TP53 4746/4885SMN1; SMN2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.